VivoSim Labs (NASDAQ:VIVS) Announces Quarterly Earnings Results

VivoSim Labs (NASDAQ:VIVS) issued its quarterly earnings data on Tuesday. The company reported ($2.21) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.04 million for the quarter. VivoSim Labs had a negative return on equity of 15.51% and a negative net margin of 861.27%.

VivoSim Labs Trading Up 2.2%

NASDAQ:VIVS opened at $0.85 on Thursday. VivoSim Labs has a 12-month low of $0.78 and a 12-month high of $5.30. The stock’s 50 day simple moving average is $1.16 and its 200-day simple moving average is $1.60. The firm has a market cap of $2.23 million, a P/E ratio of -0.16 and a beta of 1.40.

Institutional Investors Weigh In On VivoSim Labs

An institutional investor recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 8.23% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.